Human Genome Epidemiology Literature Finder
Records 1 - 4 (of 4 Records) |
Query Trace: Colitis and CYP2C19[original query] |
---|
Phase I pharmacokinetic and pharmacogenomic study of E7070 administered once every 21 days. Cancer science 2005 Oct 96 (10): 721-8. Yamada Yasuhide, Yamamoto Noboru, Shimoyama Tatsu, Horiike Atsushi, Fujisaka Yasuhito, Takayama Kyoko, Sakamoto Terumi, Nishioka Yuki, Yasuda Sanae, Tamura Tomohi |
CYP2C19 polymorphism has no correlation with the efficacy and safety of thalidomide in the treatment of immune-related bowel disease. Journal of digestive diseases 2020 Jan . Feng Rui, Xu Ping Ping, Chen Bai Li, Mao Ren, Zhang Sheng Hong, Qiu Yun, Zeng Zhi Rong, Chen Min Hu, He Y |
The impact of cytochrome P450 3A genetic polymorphisms on tacrolimus pharmacokinetics in ulcerative colitis patients. PloS one 2021 16 (4): e0250597. Furuse Maizumi, Hosomi Shuhei, Nishida Yu, Itani Shigehiro, Nadatani Yuji, Fukunaga Shusei, Otani Koji, Tanaka Fumio, Nagami Yasuaki, Taira Koichi, Kamata Noriko, Watanabe Toshio, Watanabe Kenji, Fujiwara Yasuhi |
CYP2C19 Genotype Is Not Associated With the Risk of Microscopic Colitis. Gastro hep advances 2023 7 2 (2): 242-243. K C Darlington, A F Peery, T O Keku, J T Woosley, R S Sandl |
- Page last reviewed:Feb 1, 2024
- Page last updated:Apr 22, 2024
- Content source: